Insmed Competitors

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Insmed (NASDAQ:INSM) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk and profitability.

Valuation & Earnings

This table compares Jazz Pharmaceuticals and Insmed's top-line revenue, earnings per share (EPS) and valuation.

Jazz Pharmaceuticals has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Jazz Pharmaceuticals and Insmed's net margins, return on equity and return on assets.

Institutional and Insider Ownership

95.7% of Jazz Pharmaceuticals shares are held by institutional investors. 4.6% of Jazz Pharmaceuticals shares are held by company insiders. Comparatively, 4.6% of Insmed shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Volatility and Risk

Jazz Pharmaceuticals has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500. Comparatively, Insmed has a beta of 2.43, indicating that its stock price is 143% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and target prices for Jazz Pharmaceuticals and Insmed, as reported by MarketBeat.com.

Jazz Pharmaceuticals currently has a consensus target price of $192.6250, suggesting a potential upside of 9.09%. Insmed has a consensus target price of $53.5714, suggesting a potential upside of 100.42%. Given Insmed's stronger consensus rating and higher possible upside, analysts clearly believe Insmed is more favorable than Jazz Pharmaceuticals.

Summary

Jazz Pharmaceuticals beats Insmed on 9 of the 14 factors compared between the two stocks.

Bausch Health Companies (NYSE:BHC) and Insmed (NASDAQ:INSM) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk and profitability.

Volatility and Risk

Bausch Health Companies has a beta of 1.47, indicating that its stock price is 47% more volatile than the S&P 500. Comparatively, Insmed has a beta of 2.43, indicating that its stock price is 143% more volatile than the S&P 500.

Institutional and Insider Ownership

62.9% of Bausch Health Companies shares are held by institutional investors. 12.1% of Bausch Health Companies shares are held by company insiders. Comparatively, 4.6% of Insmed shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current ratings and target prices for Bausch Health Companies and Insmed, as reported by MarketBeat.com.

Bausch Health Companies currently has a consensus target price of $34.80, suggesting a potential upside of 25.13%. Insmed has a consensus target price of $53.5714, suggesting a potential upside of 100.42%. Given Insmed's stronger consensus rating and higher possible upside, analysts clearly believe Insmed is more favorable than Bausch Health Companies.

Profitability

This table compares Bausch Health Companies and Insmed's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Bausch Health Companies and Insmed's top-line revenue, earnings per share (EPS) and valuation.

Insmed has lower revenue, but higher earnings than Bausch Health Companies. Insmed is trading at a lower price-to-earnings ratio than Bausch Health Companies, indicating that it is currently the more affordable of the two stocks.

Summary

Bausch Health Companies beats Insmed on 8 of the 14 factors compared between the two stocks.

Insmed (NASDAQ:INSM) and Maravai LifeSciences (NASDAQ:MRVI) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent ratings for Insmed and Maravai LifeSciences, as provided by MarketBeat.

Insmed currently has a consensus target price of $53.5714, indicating a potential upside of 100.42%. Maravai LifeSciences has a consensus target price of $38.3750, indicating a potential upside of 6.21%. Given Insmed's higher possible upside, equities analysts plainly believe Insmed is more favorable than Maravai LifeSciences.

Profitability

This table compares Insmed and Maravai LifeSciences' net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Insmed and Maravai LifeSciences' gross revenue, earnings per share and valuation.

Maravai LifeSciences has lower revenue, but higher earnings than Insmed.

Summary

Maravai LifeSciences beats Insmed on 4 of the 6 factors compared between the two stocks.

Insmed (NASDAQ:INSM) and United Therapeutics (NASDAQ:UTHR) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership and analyst recommendations.

Insider & Institutional Ownership

90.1% of United Therapeutics shares are owned by institutional investors. 4.6% of Insmed shares are owned by company insiders. Comparatively, 10.9% of United Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Insmed and United Therapeutics' gross revenue, earnings per share and valuation.

United Therapeutics has higher revenue and earnings than Insmed. United Therapeutics is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Insmed and United Therapeutics' net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of recent ratings for Insmed and United Therapeutics, as provided by MarketBeat.

Insmed currently has a consensus target price of $53.5714, indicating a potential upside of 100.42%. United Therapeutics has a consensus target price of $227.1429, indicating a potential upside of 15.79%. Given Insmed's higher possible upside, equities analysts plainly believe Insmed is more favorable than United Therapeutics.

Risk & Volatility

Insmed has a beta of 2.43, indicating that its stock price is 143% more volatile than the S&P 500. Comparatively, United Therapeutics has a beta of 0.52, indicating that its stock price is 48% less volatile than the S&P 500.

Summary

United Therapeutics beats Insmed on 9 of the 12 factors compared between the two stocks.

Mirati Therapeutics (NASDAQ:MRTX) and Insmed (NASDAQ:INSM) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings.

Insider & Institutional Ownership

94.9% of Mirati Therapeutics shares are owned by institutional investors. 4.1% of Mirati Therapeutics shares are owned by company insiders. Comparatively, 4.6% of Insmed shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Mirati Therapeutics and Insmed's revenue, earnings per share and valuation.

Mirati Therapeutics has higher earnings, but lower revenue than Insmed. Mirati Therapeutics is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Mirati Therapeutics and Insmed's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Mirati Therapeutics and Insmed, as provided by MarketBeat.com.

Mirati Therapeutics presently has a consensus price target of $225.2308, indicating a potential upside of 46.38%. Insmed has a consensus price target of $53.5714, indicating a potential upside of 100.42%. Given Insmed's stronger consensus rating and higher possible upside, analysts plainly believe Insmed is more favorable than Mirati Therapeutics.

Risk and Volatility

Mirati Therapeutics has a beta of 1.64, suggesting that its share price is 64% more volatile than the S&P 500. Comparatively, Insmed has a beta of 2.43, suggesting that its share price is 143% more volatile than the S&P 500.

Summary

Insmed beats Mirati Therapeutics on 8 of the 14 factors compared between the two stocks.

BridgeBio Pharma (NASDAQ:BBIO) and Insmed (NASDAQ:INSM) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings.

Analyst Recommendations

This is a summary of recent recommendations and price targets for BridgeBio Pharma and Insmed, as provided by MarketBeat.com.

BridgeBio Pharma presently has a consensus price target of $71.6667, indicating a potential upside of 44.64%. Insmed has a consensus price target of $53.5714, indicating a potential upside of 100.42%. Given Insmed's stronger consensus rating and higher possible upside, analysts plainly believe Insmed is more favorable than BridgeBio Pharma.

Insider & Institutional Ownership

95.5% of BridgeBio Pharma shares are owned by institutional investors. 40.3% of BridgeBio Pharma shares are owned by company insiders. Comparatively, 4.6% of Insmed shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares BridgeBio Pharma and Insmed's revenue, earnings per share and valuation.

Insmed has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

BridgeBio Pharma has a beta of 0.82, suggesting that its share price is 18% less volatile than the S&P 500. Comparatively, Insmed has a beta of 2.43, suggesting that its share price is 143% more volatile than the S&P 500.

Profitability

This table compares BridgeBio Pharma and Insmed's net margins, return on equity and return on assets.

Summary

Insmed beats BridgeBio Pharma on 8 of the 14 factors compared between the two stocks.